Response of Degarelix treatment in human prostate cancer monitored by HR-MAS 1H NMR spectroscopy.

Basetti MadhuGreg L ShawAnne Y WarrenDavid E NealJohn R Griffiths

Published in: Metabolomics : Official journal of the Metabolomic Society (2016)

The reduced concentrations of lactate and t-choline metabolites due to Degarelix could in principle be monitored by in vivo 1H MRS, which suggests that it would be possible to monitor the effects of physical or chemical castration in patients by that non-invasive method.

Keyphrases

prostate cancer
end stage renal disease
endothelial cells
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
mental health
physical activity
ms ms